In a research report released yesterday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and a price target of $145.00 a share, representing a potential upside of 17% from where the stock is currently trading.
The following bullets contain some highlights from that call:
- Xifaxan has been the workhorse for the last 10 years. It is on pace for $717M in 2014E, and with 90% gross and ~ 65% pretax margins, it is ~ 90% of EPS. Y/Y growth has now reaccelerated to ~20%, and the single biggest catalyst should be positive P3 IBS data in July, which would make this a $2B drug in our view.
- With the Santarus acquisition, it now provides 10 drugs for Salix and an expansion into primary care. With the + Relistor panel June 12, there could be $1B of upside not yet in our numbers.
- In a sector that thrives on growth, most Spec Pharma companies have had to “buy” growth. But since Salix has done it mostly organically, we think longer-term mid-teens growth is sustainable.
- Potential catalysts: 1) investor day July 9, 2) numbers coming up after the positive Relistor AdCom June 12; 3) Xifaxan IBS data soon is most important and we expect success; 4) Sept. 15 PDUFA date for budesonide rectal foam; 5) Salix is an excellent take-over target; 6) Salix itself could acquire an ex-US company for a tax “inversion” play.
“Our investment thesis on Salix hinges mostly on its impressive growth outlook. For a $7B market cap company, it has one of the highest projected growth rates among Spec Pharma names. Since most of that growth is driven by one large drug with a long life cycle, we see that growth as being sustainable for the next several years. We even see it being able to overcome the expected entry of generics on both Glumetza and Zegrid in 2016. We also see little binary risk but the stock seems to disagree with this, and this is the crux of our BUY rating. We would encourage investors to be buying the stock in front of the Phase 3 target 3 IBS data coming in early July since our sense is that most investors are not willing to take that risk. Hence we see the stock trading up much closer to our price target if the data are positive”, Davis wrote.
Alluvial Fund performance update for the month ended May 2021. Q1 2021 hedge fund letters, conferences and more Dear Partners and Colleagues, Alluvial Fund, LP returned 5.4% in May, compared to 0.2% for the Russell 2000 and 1.0% for the MSCI World Small+MicroCap . . . SORRY! This content is exclusively for paying members. SIGN UP Read More
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Corey Davis currently has an average return of 41.4% and a 88% success rate. Davis has a 35.5% average profit recommending SLXP, and he is ranked #24 out of 3135 analysts.